TL
TPG Life Sciences Innovations
TPG Life Sciences Innovations is a Series A to Series C stage investment firm. It has made 7 investments. 36% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deal in the last 12 months vs 2 prior). Their most common stage is series-b (64% of deals). Average disclosed round size is $892.3M (across 9 rounds with reported amounts).
Portfolio
7
Fund Size
—
Top Stage
Series B
Last 12 Mo
1
Team
CN
Carolyn Ng
Partner and Managing Director
SF
Shinichiro Fuse
Partner
SL
Sonia Lombroso
Intern
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
11 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Sling Therapeutics | Series C | $123M | Jan 2026 |
| MMRM Health | Series B | — | Sep 2025 |
 Adcendo | Series B | $135M | Nov 2024 |
| AAdcendo ApS | Series B | $135M | Nov 2024 |
| AAdcendo ApS | Series B | $135M | Jan 2024 |
| BBicara Therapeutics | Series C | $165M | Dec 2023 |
 Odyssey Therapeutics | Series B | $168M | Oct 2022 |
| Sling Therapeutics | Series A | $35M | Jun 2022 |
| AAdcendo ApS | Series B | $135M | Jan 2021 |
| CCurium | Unknown | $7B | — |
| BBicara Therapeutics | Series B | — | — |
Top Co-Investors
Logos Capital5 shared
OrbiMed5 shared
Pontifax4 shared
Ysios Capital4 shared
Dawn Biopharma4 shared
HealthCap4 shared
Surveyor Capital4 shared
Gilde Healthcare4 shared
Novo Capital4 shared
RA Capital Management4 shared
KKR2 shared
TPG Biotech2 shared
Forbion2 shared
Sectoral Asset Management2 shared
Ardian1 shared
Goldman Sachs Alternatives1 shared
ICG plc1 shared
Braidwell LP1 shared
Deerfield1 shared
Last updated: 19 September 2026